We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effects of a Potent and Selective PPAR-a Agonist in Patients With Atherogenic Dyslipidemia or Hypercholesterolemia.
- Authors
Nissen, Steven E.; Nicholls, Stephen J.; Wolski, Kathy; Howey, Daniel C.; McErlean, Ellen; Wang, Ming-Dauh; Gomez, Elisa V.; Russo, John M.
- Abstract
The article discusses the results of randomized controlled trials that examined the safety and efficacy of the drug LY518674, a peroxisome proliferator-activated receptor α agonist, in the treatment of patients with atherogenic dyslipidemia or hypercholesterolemia. Atherogenic dyslipidemia is marked by low levels of high-density lipoprotein cholesterol (HDL-C), while hypercholesterolemia is marked by elevated levels of low-density lipoprotein cholesterol. The effects of LY518674 on the levels of HDL-C, LDL-C, triglycerides, and serum creatinine. In patients with dyslipidemia the fibrate fenofibrate was also given, while patients with hypercholesterolemia were also given atorvastatin.
- Subjects
LIPID metabolism disorders; HYPERCHOLESTEREMIA; BLOOD cholesterol; FENOFIBRATE; RANDOMIZED controlled trials; TRIGLYCERIDES; LIPOPROTEINS; LOW density lipoproteins; HIGH density lipoproteins
- Publication
JAMA: Journal of the American Medical Association, 2007, Vol 297, Issue 12, p1362
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.297.12.1362